Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRE | P78334 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995029 | 0.86 | TLR4 (0.39) | ALDH1A1CYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL30727078 | 0.86 | TLR4 (0.39) | ALDH1A1CYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL18372761 | 0.83 | ALDH1A1 (0.36) | ALDH1A1MAPTL3MBTL1POLBATM | |
| SCHEMBL19140550 | 0.81 | ALDH1A1 (0.35) | ALDH1A1MAPTL3MBTL1ATMKDM4E | |
| SCHEMBL16505741 | 0.80 | ALDH1A1 (0.36) | ALDH1A1MAPTL3MBTL1POLBATM | |
| SCHEMBL17338856 | 0.79 | TLR4 (0.33) | ALDH1A1L3MBTL1 | |
| SCHEMBL12555452 | 0.78 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL30721778 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL31013161 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CYP3A4CYP2C9CYP2C19GABRP | |
| SCHEMBL22887951 | 0.76 | MAPT (0.33) | ALDH1A1MAPTL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| WO-2020112846-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2020-06-04 | — | — | WO | disclosed |
| WO-2020112846-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20200039941-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH | 2020-02-06 | — | — | US | disclosed |
| US-20200039941-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH | 2020-02-06 | — | — | US | disclosed |
| US-10435375-B2 | CXCR4 chemokine receptor modulators | NORTHWESTERN UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435375-B2 | CXCR4 chemokine receptor modulators | NORTHWESTERN UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NORTHWESTERN UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NORTHWESTERN UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NORTHWESTERN UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | LAGU BHARAT | 2009-04-16 | — | — | US | disclosed |
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| US-7452997-B2 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-18 | — | — | US | disclosed |
| EP-1735286-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-27 | — | — | EP | disclosed |
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005095353-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435375-B2 | CXCR4 chemokine receptor modulators | CXCR4, ACKR3, CXCR3 | ALDH1A1 2896/4885CYP3A4 4592/4885CYP2C9 4807/4885 |
| US-20050228034-A1 | Tetrahydro-indazole cannabinoid modulators | CNR2, CNR1, GPR18 | ALDH1A1 1597/4885CYP3A4 755/4885CYP2C9 732/4885 |
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | FFAR1, HCAR1, GPR119 | ALDH1A1 949/4885CYP3A4 763/4885CYP2C9 743/4885 |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | CXCR4, ACKR3, CXCR3 | ALDH1A1 2896/4885CYP3A4 4592/4885CYP2C9 4807/4885 |
| US-20090099143-A1 | TETRAHYDRO-INDAZOLE CANNABINOID MODULATORS | CNR2, CNR1, GPR18 | ALDH1A1 1597/4885CYP3A4 755/4885CYP2C9 732/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | ALDH1A1 1394/4885CYP3A4 658/4885CYP2C9 1042/4885 |
| US-20200039941-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | CXCR4, ACKR3, CXCR3 | ALDH1A1 2896/4885CYP3A4 4592/4885CYP2C9 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.